Inflammatory disease activity in relapsing-remitting multiple sclerosis
Potential benefit studied: Investigated for reduction in MRI signs of inflammation
Supporting researchA human pilot study found fewer active inflammatory brain lesions on MRI during treatment with a standardized frankincense extract.
The SABA pilot enrolled 38 people; 28 completed eight months of treatment after a four-month baseline period. A linked analysis describes daily standardized frankincense amounts of 3,600 to 4,800 mg in those 28 participants.
The pilot tested a specific standardized extract in gram quantities each day. It does not establish equivalent exposure or MS benefits from Mobility's 100 mg Boswellia at 30% AKBA combined with moringa.
The doses above describe research, not personal dosing instructions. Ingredient studies do not diagnose symptoms or establish medical suitability. Discuss medicines, existing conditions and treatment decisions with an appropriate healthcare professional.